The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Dual-Antibody ADC Market Research Report 2025
Synopsis
The global market for Dual-Antibody ADC was valued at US$ 522 million in the year 2024 and is projected to reach a revised size of US$ 736 million by 2031, growing at a CAGR of 5.7% during the forecast period.
Dual-Antibody ADC is an innovative targeted therapy that combines a bispecific antibody with a cytotoxic payload, enabling simultaneous recognition of two tumor-associated antigens and precise delivery of potent toxins to cancer cells. Compared to conventional ADCs, dual-antibody ADCs exhibit enhanced tumor selectivity and reduced off-target toxicity, potentially improving therapeutic efficacy while minimizing side effects. These drugs show promising applications in both hematological malignancies and solid tumors, representing a cutting-edge research focus in targeted cancer therapy.
North American market for Dual-Antibody ADC is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Dual-Antibody ADC is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Dual-Antibody ADC in Solid Tumors is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Dual-Antibody ADC include Sichuan Biokin Pharmaceutical, Doma Biopharmaceutical, VelaVigo, Hangzhou DAC Biotechnology, Biocy Togen, Innovent Biologics, Zymeworks, AstraZeneca, Regeneron Pharmaceuticals, Sutro Biopharma/Merck, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Dual-Antibody ADC, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dual-Antibody ADC.
The Dual-Antibody ADC market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Dual-Antibody ADC market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Dual-Antibody ADC companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sichuan Biokin Pharmaceutical
Doma Biopharmaceutical
VelaVigo
Hangzhou DAC Biotechnology
Biocy Togen
Innovent Biologics
Zymeworks
AstraZeneca
Regeneron Pharmaceuticals
Sutro Biopharma/Merck
Alphamab Oncology
Coherent Biopharma
Sichuan Kelun Pharmaceutical
Akeso
Segment by Type
Dual-Target ADC
Dual-Epitope ADC
Segment by Application
Solid Tumors
Non-Solid Tumors
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Dual-Antibody ADC company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global market for Dual-Antibody ADC was valued at US$ 522 million in the year 2024 and is projected to reach a revised size of US$ 736 million by 2031, growing at a CAGR of 5.7% during the forecast period.
Dual-Antibody ADC is an innovative targeted therapy that combines a bispecific antibody with a cytotoxic payload, enabling simultaneous recognition of two tumor-associated antigens and precise delivery of potent toxins to cancer cells. Compared to conventional ADCs, dual-antibody ADCs exhibit enhanced tumor selectivity and reduced off-target toxicity, potentially improving therapeutic efficacy while minimizing side effects. These drugs show promising applications in both hematological malignancies and solid tumors, representing a cutting-edge research focus in targeted cancer therapy.
North American market for Dual-Antibody ADC is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Dual-Antibody ADC is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Dual-Antibody ADC in Solid Tumors is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Dual-Antibody ADC include Sichuan Biokin Pharmaceutical, Doma Biopharmaceutical, VelaVigo, Hangzhou DAC Biotechnology, Biocy Togen, Innovent Biologics, Zymeworks, AstraZeneca, Regeneron Pharmaceuticals, Sutro Biopharma/Merck, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Dual-Antibody ADC, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dual-Antibody ADC.
The Dual-Antibody ADC market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Dual-Antibody ADC market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Dual-Antibody ADC companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sichuan Biokin Pharmaceutical
Doma Biopharmaceutical
VelaVigo
Hangzhou DAC Biotechnology
Biocy Togen
Innovent Biologics
Zymeworks
AstraZeneca
Regeneron Pharmaceuticals
Sutro Biopharma/Merck
Alphamab Oncology
Coherent Biopharma
Sichuan Kelun Pharmaceutical
Akeso
Segment by Type
Dual-Target ADC
Dual-Epitope ADC
Segment by Application
Solid Tumors
Non-Solid Tumors
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Dual-Antibody ADC company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Dual-Antibody ADC Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Dual-Target ADC
1.2.3 Dual-Epitope ADC
1.3 Market by Application
1.3.1 Global Dual-Antibody ADC Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Solid Tumors
1.3.3 Non-Solid Tumors
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Dual-Antibody ADC Market Perspective (2020-2031)
2.2 Global Dual-Antibody ADC Growth Trends by Region
2.2.1 Global Dual-Antibody ADC Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Dual-Antibody ADC Historic Market Size by Region (2020-2025)
2.2.3 Dual-Antibody ADC Forecasted Market Size by Region (2026-2031)
2.3 Dual-Antibody ADC Market Dynamics
2.3.1 Dual-Antibody ADC Industry Trends
2.3.2 Dual-Antibody ADC Market Drivers
2.3.3 Dual-Antibody ADC Market Challenges
2.3.4 Dual-Antibody ADC Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Dual-Antibody ADC Players by Revenue
3.1.1 Global Top Dual-Antibody ADC Players by Revenue (2020-2025)
3.1.2 Global Dual-Antibody ADC Revenue Market Share by Players (2020-2025)
3.2 Global Top Dual-Antibody ADC Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Dual-Antibody ADC Revenue
3.4 Global Dual-Antibody ADC Market Concentration Ratio
3.4.1 Global Dual-Antibody ADC Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Dual-Antibody ADC Revenue in 2024
3.5 Global Key Players of Dual-Antibody ADC Head office and Area Served
3.6 Global Key Players of Dual-Antibody ADC, Product and Application
3.7 Global Key Players of Dual-Antibody ADC, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Dual-Antibody ADC Breakdown Data by Type
4.1 Global Dual-Antibody ADC Historic Market Size by Type (2020-2025)
4.2 Global Dual-Antibody ADC Forecasted Market Size by Type (2026-2031)
5 Dual-Antibody ADC Breakdown Data by Application
5.1 Global Dual-Antibody ADC Historic Market Size by Application (2020-2025)
5.2 Global Dual-Antibody ADC Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Dual-Antibody ADC Market Size (2020-2031)
6.2 North America Dual-Antibody ADC Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Dual-Antibody ADC Market Size by Country (2020-2025)
6.4 North America Dual-Antibody ADC Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Dual-Antibody ADC Market Size (2020-2031)
7.2 Europe Dual-Antibody ADC Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Dual-Antibody ADC Market Size by Country (2020-2025)
7.4 Europe Dual-Antibody ADC Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Dual-Antibody ADC Market Size (2020-2031)
8.2 Asia-Pacific Dual-Antibody ADC Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Dual-Antibody ADC Market Size by Region (2020-2025)
8.4 Asia-Pacific Dual-Antibody ADC Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Dual-Antibody ADC Market Size (2020-2031)
9.2 Latin America Dual-Antibody ADC Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Dual-Antibody ADC Market Size by Country (2020-2025)
9.4 Latin America Dual-Antibody ADC Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Dual-Antibody ADC Market Size (2020-2031)
10.2 Middle East & Africa Dual-Antibody ADC Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Dual-Antibody ADC Market Size by Country (2020-2025)
10.4 Middle East & Africa Dual-Antibody ADC Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sichuan Biokin Pharmaceutical
11.1.1 Sichuan Biokin Pharmaceutical Company Details
11.1.2 Sichuan Biokin Pharmaceutical Business Overview
11.1.3 Sichuan Biokin Pharmaceutical Dual-Antibody ADC Introduction
11.1.4 Sichuan Biokin Pharmaceutical Revenue in Dual-Antibody ADC Business (2020-2025)
11.1.5 Sichuan Biokin Pharmaceutical Recent Development
11.2 Doma Biopharmaceutical
11.2.1 Doma Biopharmaceutical Company Details
11.2.2 Doma Biopharmaceutical Business Overview
11.2.3 Doma Biopharmaceutical Dual-Antibody ADC Introduction
11.2.4 Doma Biopharmaceutical Revenue in Dual-Antibody ADC Business (2020-2025)
11.2.5 Doma Biopharmaceutical Recent Development
11.3 VelaVigo
11.3.1 VelaVigo Company Details
11.3.2 VelaVigo Business Overview
11.3.3 VelaVigo Dual-Antibody ADC Introduction
11.3.4 VelaVigo Revenue in Dual-Antibody ADC Business (2020-2025)
11.3.5 VelaVigo Recent Development
11.4 Hangzhou DAC Biotechnology
11.4.1 Hangzhou DAC Biotechnology Company Details
11.4.2 Hangzhou DAC Biotechnology Business Overview
11.4.3 Hangzhou DAC Biotechnology Dual-Antibody ADC Introduction
11.4.4 Hangzhou DAC Biotechnology Revenue in Dual-Antibody ADC Business (2020-2025)
11.4.5 Hangzhou DAC Biotechnology Recent Development
11.5 Biocy Togen
11.5.1 Biocy Togen Company Details
11.5.2 Biocy Togen Business Overview
11.5.3 Biocy Togen Dual-Antibody ADC Introduction
11.5.4 Biocy Togen Revenue in Dual-Antibody ADC Business (2020-2025)
11.5.5 Biocy Togen Recent Development
11.6 Innovent Biologics
11.6.1 Innovent Biologics Company Details
11.6.2 Innovent Biologics Business Overview
11.6.3 Innovent Biologics Dual-Antibody ADC Introduction
11.6.4 Innovent Biologics Revenue in Dual-Antibody ADC Business (2020-2025)
11.6.5 Innovent Biologics Recent Development
11.7 Zymeworks
11.7.1 Zymeworks Company Details
11.7.2 Zymeworks Business Overview
11.7.3 Zymeworks Dual-Antibody ADC Introduction
11.7.4 Zymeworks Revenue in Dual-Antibody ADC Business (2020-2025)
11.7.5 Zymeworks Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Details
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Dual-Antibody ADC Introduction
11.8.4 AstraZeneca Revenue in Dual-Antibody ADC Business (2020-2025)
11.8.5 AstraZeneca Recent Development
11.9 Regeneron Pharmaceuticals
11.9.1 Regeneron Pharmaceuticals Company Details
11.9.2 Regeneron Pharmaceuticals Business Overview
11.9.3 Regeneron Pharmaceuticals Dual-Antibody ADC Introduction
11.9.4 Regeneron Pharmaceuticals Revenue in Dual-Antibody ADC Business (2020-2025)
11.9.5 Regeneron Pharmaceuticals Recent Development
11.10 Sutro Biopharma/Merck
11.10.1 Sutro Biopharma/Merck Company Details
11.10.2 Sutro Biopharma/Merck Business Overview
11.10.3 Sutro Biopharma/Merck Dual-Antibody ADC Introduction
11.10.4 Sutro Biopharma/Merck Revenue in Dual-Antibody ADC Business (2020-2025)
11.10.5 Sutro Biopharma/Merck Recent Development
11.11 Alphamab Oncology
11.11.1 Alphamab Oncology Company Details
11.11.2 Alphamab Oncology Business Overview
11.11.3 Alphamab Oncology Dual-Antibody ADC Introduction
11.11.4 Alphamab Oncology Revenue in Dual-Antibody ADC Business (2020-2025)
11.11.5 Alphamab Oncology Recent Development
11.12 Coherent Biopharma
11.12.1 Coherent Biopharma Company Details
11.12.2 Coherent Biopharma Business Overview
11.12.3 Coherent Biopharma Dual-Antibody ADC Introduction
11.12.4 Coherent Biopharma Revenue in Dual-Antibody ADC Business (2020-2025)
11.12.5 Coherent Biopharma Recent Development
11.13 Sichuan Kelun Pharmaceutical
11.13.1 Sichuan Kelun Pharmaceutical Company Details
11.13.2 Sichuan Kelun Pharmaceutical Business Overview
11.13.3 Sichuan Kelun Pharmaceutical Dual-Antibody ADC Introduction
11.13.4 Sichuan Kelun Pharmaceutical Revenue in Dual-Antibody ADC Business (2020-2025)
11.13.5 Sichuan Kelun Pharmaceutical Recent Development
11.14 Akeso
11.14.1 Akeso Company Details
11.14.2 Akeso Business Overview
11.14.3 Akeso Dual-Antibody ADC Introduction
11.14.4 Akeso Revenue in Dual-Antibody ADC Business (2020-2025)
11.14.5 Akeso Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of TablesList of Tables
Table 1. Global Dual-Antibody ADC Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Dual-Target ADC
Table 3. Key Players of Dual-Epitope ADC
Table 4. Global Dual-Antibody ADC Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Dual-Antibody ADC Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Dual-Antibody ADC Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Dual-Antibody ADC Market Share by Region (2020-2025)
Table 8. Global Dual-Antibody ADC Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Dual-Antibody ADC Market Share by Region (2026-2031)
Table 10. Dual-Antibody ADC Market Trends
Table 11. Dual-Antibody ADC Market Drivers
Table 12. Dual-Antibody ADC Market Challenges
Table 13. Dual-Antibody ADC Market Restraints
Table 14. Global Dual-Antibody ADC Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Dual-Antibody ADC Market Share by Players (2020-2025)
Table 16. Global Top Dual-Antibody ADC Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dual-Antibody ADC as of 2024)
Table 17. Ranking of Global Top Dual-Antibody ADC Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Dual-Antibody ADC Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Dual-Antibody ADC, Headquarters and Area Served
Table 20. Global Key Players of Dual-Antibody ADC, Product and Application
Table 21. Global Key Players of Dual-Antibody ADC, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Dual-Antibody ADC Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Dual-Antibody ADC Revenue Market Share by Type (2020-2025)
Table 25. Global Dual-Antibody ADC Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Dual-Antibody ADC Revenue Market Share by Type (2026-2031)
Table 27. Global Dual-Antibody ADC Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Dual-Antibody ADC Revenue Market Share by Application (2020-2025)
Table 29. Global Dual-Antibody ADC Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Dual-Antibody ADC Revenue Market Share by Application (2026-2031)
Table 31. North America Dual-Antibody ADC Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Dual-Antibody ADC Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Dual-Antibody ADC Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Dual-Antibody ADC Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Dual-Antibody ADC Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Dual-Antibody ADC Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Dual-Antibody ADC Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Dual-Antibody ADC Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Dual-Antibody ADC Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Dual-Antibody ADC Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Dual-Antibody ADC Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Dual-Antibody ADC Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Dual-Antibody ADC Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Dual-Antibody ADC Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Dual-Antibody ADC Market Size by Country (2026-2031) & (US$ Million)
Table 46. Sichuan Biokin Pharmaceutical Company Details
Table 47. Sichuan Biokin Pharmaceutical Business Overview
Table 48. Sichuan Biokin Pharmaceutical Dual-Antibody ADC Product
Table 49. Sichuan Biokin Pharmaceutical Revenue in Dual-Antibody ADC Business (2020-2025) & (US$ Million)
Table 50. Sichuan Biokin Pharmaceutical Recent Development
Table 51. Doma Biopharmaceutical Company Details
Table 52. Doma Biopharmaceutical Business Overview
Table 53. Doma Biopharmaceutical Dual-Antibody ADC Product
Table 54. Doma Biopharmaceutical Revenue in Dual-Antibody ADC Business (2020-2025) & (US$ Million)
Table 55. Doma Biopharmaceutical Recent Development
Table 56. VelaVigo Company Details
Table 57. VelaVigo Business Overview
Table 58. VelaVigo Dual-Antibody ADC Product
Table 59. VelaVigo Revenue in Dual-Antibody ADC Business (2020-2025) & (US$ Million)
Table 60. VelaVigo Recent Development
Table 61. Hangzhou DAC Biotechnology Company Details
Table 62. Hangzhou DAC Biotechnology Business Overview
Table 63. Hangzhou DAC Biotechnology Dual-Antibody ADC Product
Table 64. Hangzhou DAC Biotechnology Revenue in Dual-Antibody ADC Business (2020-2025) & (US$ Million)
Table 65. Hangzhou DAC Biotechnology Recent Development
Table 66. Biocy Togen Company Details
Table 67. Biocy Togen Business Overview
Table 68. Biocy Togen Dual-Antibody ADC Product
Table 69. Biocy Togen Revenue in Dual-Antibody ADC Business (2020-2025) & (US$ Million)
Table 70. Biocy Togen Recent Development
Table 71. Innovent Biologics Company Details
Table 72. Innovent Biologics Business Overview
Table 73. Innovent Biologics Dual-Antibody ADC Product
Table 74. Innovent Biologics Revenue in Dual-Antibody ADC Business (2020-2025) & (US$ Million)
Table 75. Innovent Biologics Recent Development
Table 76. Zymeworks Company Details
Table 77. Zymeworks Business Overview
Table 78. Zymeworks Dual-Antibody ADC Product
Table 79. Zymeworks Revenue in Dual-Antibody ADC Business (2020-2025) & (US$ Million)
Table 80. Zymeworks Recent Development
Table 81. AstraZeneca Company Details
Table 82. AstraZeneca Business Overview
Table 83. AstraZeneca Dual-Antibody ADC Product
Table 84. AstraZeneca Revenue in Dual-Antibody ADC Business (2020-2025) & (US$ Million)
Table 85. AstraZeneca Recent Development
Table 86. Regeneron Pharmaceuticals Company Details
Table 87. Regeneron Pharmaceuticals Business Overview
Table 88. Regeneron Pharmaceuticals Dual-Antibody ADC Product
Table 89. Regeneron Pharmaceuticals Revenue in Dual-Antibody ADC Business (2020-2025) & (US$ Million)
Table 90. Regeneron Pharmaceuticals Recent Development
Table 91. Sutro Biopharma/Merck Company Details
Table 92. Sutro Biopharma/Merck Business Overview
Table 93. Sutro Biopharma/Merck Dual-Antibody ADC Product
Table 94. Sutro Biopharma/Merck Revenue in Dual-Antibody ADC Business (2020-2025) & (US$ Million)
Table 95. Sutro Biopharma/Merck Recent Development
Table 96. Alphamab Oncology Company Details
Table 97. Alphamab Oncology Business Overview
Table 98. Alphamab Oncology Dual-Antibody ADC Product
Table 99. Alphamab Oncology Revenue in Dual-Antibody ADC Business (2020-2025) & (US$ Million)
Table 100. Alphamab Oncology Recent Development
Table 101. Coherent Biopharma Company Details
Table 102. Coherent Biopharma Business Overview
Table 103. Coherent Biopharma Dual-Antibody ADC Product
Table 104. Coherent Biopharma Revenue in Dual-Antibody ADC Business (2020-2025) & (US$ Million)
Table 105. Coherent Biopharma Recent Development
Table 106. Sichuan Kelun Pharmaceutical Company Details
Table 107. Sichuan Kelun Pharmaceutical Business Overview
Table 108. Sichuan Kelun Pharmaceutical Dual-Antibody ADC Product
Table 109. Sichuan Kelun Pharmaceutical Revenue in Dual-Antibody ADC Business (2020-2025) & (US$ Million)
Table 110. Sichuan Kelun Pharmaceutical Recent Development
Table 111. Akeso Company Details
Table 112. Akeso Business Overview
Table 113. Akeso Dual-Antibody ADC Product
Table 114. Akeso Revenue in Dual-Antibody ADC Business (2020-2025) & (US$ Million)
Table 115. Akeso Recent Development
Table 116. Research Programs/Design for This Report
Table 117. Key Data Information from Secondary Sources
Table 118. Key Data Information from Primary Sources
Table 119. Authors List of This Report
List of Figures
Figure 1. Dual-Antibody ADC Picture
Figure 2. Global Dual-Antibody ADC Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Dual-Antibody ADC Market Share by Type: 2024 VS 2031
Figure 4. Dual-Target ADC Features
Figure 5. Dual-Epitope ADC Features
Figure 6. Global Dual-Antibody ADC Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Dual-Antibody ADC Market Share by Application: 2024 VS 2031
Figure 8. Solid Tumors Case Studies
Figure 9. Non-Solid Tumors Case Studies
Figure 10. Dual-Antibody ADC Report Years Considered
Figure 11. Global Dual-Antibody ADC Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 12. Global Dual-Antibody ADC Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Dual-Antibody ADC Market Share by Region: 2024 VS 2031
Figure 14. Global Dual-Antibody ADC Market Share by Players in 2024
Figure 15. Global Dual-Antibody ADC Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 16. The Top 10 and 5 Players Market Share by Dual-Antibody ADC Revenue in 2024
Figure 17. North America Dual-Antibody ADC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 18. North America Dual-Antibody ADC Market Share by Country (2020-2031)
Figure 19. United States Dual-Antibody ADC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. Canada Dual-Antibody ADC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Europe Dual-Antibody ADC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Dual-Antibody ADC Market Share by Country (2020-2031)
Figure 23. Germany Dual-Antibody ADC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. France Dual-Antibody ADC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. U.K. Dual-Antibody ADC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Italy Dual-Antibody ADC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Russia Dual-Antibody ADC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Nordic Countries Dual-Antibody ADC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Asia-Pacific Dual-Antibody ADC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Dual-Antibody ADC Market Share by Region (2020-2031)
Figure 31. China Dual-Antibody ADC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Japan Dual-Antibody ADC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. South Korea Dual-Antibody ADC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Southeast Asia Dual-Antibody ADC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. India Dual-Antibody ADC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Australia Dual-Antibody ADC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Latin America Dual-Antibody ADC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Dual-Antibody ADC Market Share by Country (2020-2031)
Figure 39. Mexico Dual-Antibody ADC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Brazil Dual-Antibody ADC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Middle East & Africa Dual-Antibody ADC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Dual-Antibody ADC Market Share by Country (2020-2031)
Figure 43. Turkey Dual-Antibody ADC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Saudi Arabia Dual-Antibody ADC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. UAE Dual-Antibody ADC Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Sichuan Biokin Pharmaceutical Revenue Growth Rate in Dual-Antibody ADC Business (2020-2025)
Figure 47. Doma Biopharmaceutical Revenue Growth Rate in Dual-Antibody ADC Business (2020-2025)
Figure 48. VelaVigo Revenue Growth Rate in Dual-Antibody ADC Business (2020-2025)
Figure 49. Hangzhou DAC Biotechnology Revenue Growth Rate in Dual-Antibody ADC Business (2020-2025)
Figure 50. Biocy Togen Revenue Growth Rate in Dual-Antibody ADC Business (2020-2025)
Figure 51. Innovent Biologics Revenue Growth Rate in Dual-Antibody ADC Business (2020-2025)
Figure 52. Zymeworks Revenue Growth Rate in Dual-Antibody ADC Business (2020-2025)
Figure 53. AstraZeneca Revenue Growth Rate in Dual-Antibody ADC Business (2020-2025)
Figure 54. Regeneron Pharmaceuticals Revenue Growth Rate in Dual-Antibody ADC Business (2020-2025)
Figure 55. Sutro Biopharma/Merck Revenue Growth Rate in Dual-Antibody ADC Business (2020-2025)
Figure 56. Alphamab Oncology Revenue Growth Rate in Dual-Antibody ADC Business (2020-2025)
Figure 57. Coherent Biopharma Revenue Growth Rate in Dual-Antibody ADC Business (2020-2025)
Figure 58. Sichuan Kelun Pharmaceutical Revenue Growth Rate in Dual-Antibody ADC Business (2020-2025)
Figure 59. Akeso Revenue Growth Rate in Dual-Antibody ADC Business (2020-2025)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
